Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment

The purpose of this study was to determine whether adding the anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to carboplatin/paclitaxel improved pathologic complete response (pCR) at reassessment surgery in epithelial ovarian, fallopian tube, or primary peritoneal ca...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Gynecologic oncology Ročník 119; číslo 3; s. 451 - 456
Hlavní autoři:	Blank, Stephanie V., Christos, Paul, Curtin, John P., Goldman, Noah, Runowicz, Carolyn D., Sparano, Joseph A., Liebes, Leonard, Chen, Helen X., Muggia, Franco M.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Elsevier Inc 01.12.2010
Témata:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carboplatin Carboplatin - administration & dosage Carboplatin - adverse effects Chemotherapy, Adjuvant Disease-Free Survival ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Erlotinib Erlotinib Hydrochloride Fallopian Tube Neoplasms - drug therapy Fallopian Tube Neoplasms - genetics Fallopian Tube Neoplasms - pathology Fallopian Tube Neoplasms - surgery Female Gene Amplification - drug effects Genes, erbB-1 - drug effects Hematology, Oncology and Palliative Medicine Humans Middle Aged Neoadjuvant Therapy Neoplasm Staging Obstetrics and Gynecology Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - pathology Ovarian Neoplasms - surgery Paclitaxel Paclitaxel - administration & dosage Paclitaxel - adverse effects Peritoneal Neoplasms - drug therapy Peritoneal Neoplasms - genetics Peritoneal Neoplasms - pathology Peritoneal Neoplasms - surgery Quinazolines - administration & dosage Quinazolines - adverse effects Reassessment surgery Young Adult Carboplatin Reassessment surgery Erlotinib Paclitaxel Ovarian cancer
ISSN:	0090-8258, 1095-6859, 1095-6859
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!